Stryker Corporation $SYK Shares Bought by Colonial Trust Advisors

Colonial Trust Advisors raised its holdings in Stryker Corporation (NYSE:SYK) by 1.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 29,966 shares of the medical technology company’s stock after purchasing an additional 364 shares during the period. Colonial Trust Advisors’ holdings in Stryker were worth $11,856,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of SYK. Mid American Wealth Advisory Group Inc. purchased a new stake in Stryker in the 2nd quarter valued at approximately $26,000. Elevation Point Wealth Partners LLC acquired a new position in shares of Stryker in the second quarter worth $28,000. Sachetta LLC lifted its position in shares of Stryker by 58.7% in the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after acquiring an additional 27 shares in the last quarter. Ridgewood Investments LLC boosted its stake in shares of Stryker by 48.4% during the second quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock valued at $36,000 after acquiring an additional 30 shares during the last quarter. Finally, Ransom Advisory Ltd acquired a new stake in shares of Stryker during the first quarter valued at $37,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have issued reports on SYK. BTIG Research reaffirmed a “buy” rating and set a $410.00 price target on shares of Stryker in a research note on Friday, November 14th. Royal Bank Of Canada reissued an “outperform” rating and set a $435.00 price objective on shares of Stryker in a research note on Friday, November 14th. Evercore ISI lowered their target price on shares of Stryker from $410.00 to $405.00 and set an “outperform” rating for the company in a research note on Friday, October 31st. Rothschild Redb upgraded Stryker to a “hold” rating in a report on Thursday, September 18th. Finally, UBS Group set a $408.00 price target on Stryker in a research note on Monday, October 13th. Thirteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $434.37.

Stryker Stock Performance

Shares of SYK stock opened at $372.04 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The firm has a market capitalization of $142.28 billion, a price-to-earnings ratio of 49.28, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94. Stryker Corporation has a one year low of $329.16 and a one year high of $406.19. The company has a 50 day moving average price of $369.01 and a 200 day moving average price of $380.43.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.13 by $0.06. The company had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the previous year, the company earned $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Sell-side analysts anticipate that Stryker Corporation will post 13.47 EPS for the current year.

Insider Buying and Selling at Stryker

In other news, CFO Preston Wendell Wells sold 165 shares of the business’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $365.88, for a total transaction of $60,370.20. Following the completion of the sale, the chief financial officer owned 6,694 shares in the company, valued at approximately $2,449,200.72. The trade was a 2.41% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ronda E. Stryker sold 276,173 shares of the stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the sale, the director directly owned 2,702,108 shares of the company’s stock, valued at approximately $954,600,714.24. This trade represents a 9.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 522,118 shares of company stock valued at $185,381,932. Company insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.